Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
This week in Biotech
Biotech — Aug 10 – Aug 14, 2026 (Wk 33): Biotech Week: M&A Concerns, Earnings Beats, and ETF Focus →This week in biotech saw investor attention on mergers and acquisitions, with some companies experiencing stock downgrades due to M&A concerns while others posted strong earnings. Discussions also continued around investment approaches, including broad healthcare ETFs…
AAPG
Valuation N/A
ASCENTAGE PHARMA GROUP INTERNATIONAL
Price$19.00
Model IV—
P/IV—
Limited data — see page
AARD
Valuation N/A
Aardvark Therapeutics, Inc.
Price$7.90
Model IV—
P/IV—
Limited data — see page
ABBV
Fairly valued
AbbVie Inc.
Price$250.33
Model IV$229.05
P/IV1.09
Premium +9%
Return to IV: -8.5%
Market implies +5.0%/yr
vs model +4.5% · in line
ABCL
Valuation N/A
AbCellera Biologics Inc.
Price$6.93
Model IV—
P/IV—
Market implies +98.4%/yr
vs model +2.0% · above model
ABEO
Valuation N/A
ABEONA THERAPEUTICS INC.
Price$5.99
Model IV—
P/IV—
Market implies +53.8%/yr
vs model +18.0% · above model
ABOS
Valuation N/A
Acumen Pharmaceuticals, Inc.
Price$2.44
Model IV—
P/IV—
Limited data — see page
ABSI
Valuation N/A
Absci Corp
Price$9.18
Model IV—
P/IV—
Market implies +114.8%/yr
vs model +2.0% · above model
ABVC
Valuation N/A
ABVC BIOPHARMA, INC.
Price$0.90
Model IV—
P/IV—
Market implies +60.0%/yr
vs model +2.0% · above model
ABVX
Valuation N/A
Abivax S.A.
Price$130.93
Model IV—
P/IV—
Limited data — see page
ACAD
Deeply overvalued
ACADIA PHARMACEUTICALS INC
Price$29.21
Model IV$10.33
P/IV2.10
Premium +183%
Return to IV: -64.6%
Market implies +28.4%/yr
vs model +18.4% · above model
ACET
Valuation N/A
Adicet Bio, Inc.
Price$8.38
Model IV—
P/IV—
Limited data — see page
ACHV
Valuation N/A
ACHIEVE LIFE SCIENCES, INC.
Price$6.65
Model IV—
P/IV—
Limited data — see page
ACIU
Valuation N/A
AC Immune SA
Price$2.49
Model IV—
P/IV—
Limited data — see page
ACOG
Valuation N/A
Alpha Cognition Inc.
Price$8.84
Model IV—
P/IV—
Market implies +29.9%/yr
vs model +15.0% · above model
ACRS
Valuation N/A
Aclaris Therapeutics, Inc.
Price$5.90
Model IV—
P/IV—
Market implies +37.5%/yr
vs model +3.7% · above model
ACRV
Valuation N/A
Acrivon Therapeutics, Inc.
Price$1.95
Model IV—
P/IV—
Limited data — see page
ADAG
Valuation N/A
Adagene Inc.
Price$4.11
Model IV—
P/IV—
Market implies +48.0%/yr
vs model +2.0% · above model
ADIL
Valuation N/A
ADIAL PHARMACEUTICALS, INC.
Price$3.98
Model IV—
P/IV—
Limited data — see page
ADMA
Deeply undervalued
ADMA BIOLOGICS, INC.
Price$9.47
Model IV$17.37
P/IV0.46
Discount 45%
Return to IV: +83.4%
Market implies -10.6%/yr
vs model +50.0% · below model
ADPT
Valuation N/A
Adaptive Biotechnologies Corp
Price$24.93
Model IV—
P/IV—
Market implies +41.1%/yr
vs model +15.7% · above model
ADTX
Deeply undervalued
Aditxt, Inc.
Price$0.00
Model IV$0.03
P/IV3.91
Discount 93%
Return to IV: +1,400.0%
ADVB
Valuation N/A
Advanced Biomed Inc.
Price$6.37
Model IV—
P/IV—
Limited data — see page
ADXN
Valuation N/A
Addex Therapeutics Ltd.
Price$5.95
Model IV—
P/IV—
Limited data — see page
AEON
Valuation N/A
AEON Biopharma, Inc.
Price$0.28
Model IV—
P/IV—
Limited data — see page
AGEN
Valuation N/A
AGENUS INC
Price$6.96
Model IV—
P/IV—
Market implies +48.1%/yr
vs model +2.0% · above model
AGIO
Valuation N/A
AGIOS PHARMACEUTICALS, INC.
Price$32.27
Model IV—
P/IV—
Market implies +37.4%/yr
vs model +15.0% · above model
AGMB
Valuation N/A
Agomab Therapeutics NV
Price$13.22
Model IV—
P/IV—
Limited data — see page
AIM
Valuation N/A
AIM ImmunoTech Inc.
Price$0.22
Model IV—
P/IV—
Market implies +13.3%/yr
vs model +2.0% · above model
AIMD
Valuation N/A
Ainos, Inc.
Price$1.42
Model IV—
P/IV—
Market implies +91.0%/yr
vs model +2.0% · above model
AKTS
Valuation N/A
Aktis Oncology, Inc.
Price$24.93
Model IV—
P/IV—
Limited data — see page
AKTX
Valuation N/A
Akari Therapeutics Plc
Price$7.54
Model IV—
P/IV—
Limited data — see page
ALBT
Valuation N/A
Avalon GloboCare Corp.
Price$0.22
Model IV—
P/IV—
Market implies -15.2%/yr
vs model +15.0% · below model
ALEC
Valuation N/A
Alector, Inc.
Price$1.78
Model IV—
P/IV—
Market implies +79.1%/yr
vs model +2.0% · above model
ALGS
Valuation N/A
Aligos Therapeutics, Inc.
Price$5.59
Model IV—
P/IV—
Market implies +51.7%/yr
vs model +15.0% · above model
ALKS
Fairly valued
Alkermes plc.
Price$49.17
Model IV$45.18
P/IV0.56
Premium +9%
Return to IV: -8.1%
Market implies +7.0%/yr
vs model +7.1% · in line
ALLO
Valuation N/A
Allogene Therapeutics, Inc.
Price$2.01
Model IV—
P/IV—
Market implies +150.0%/yr
vs model +15.0% · above model
ALLR
Valuation N/A
Allarity Therapeutics, Inc.
Price$1.37
Model IV—
P/IV—
Market implies +66.4%/yr
vs model +15.0% · above model
ALMR
Valuation N/A
Alamar Biosciences, Inc.
Price$33.16
Model IV—
P/IV—
Limited data — see page
ALMS
Valuation N/A
ALUMIS INC.
Price$25.31
Model IV—
P/IV—
Market implies +66.3%/yr
vs model +15.0% · above model
ALT
Valuation N/A
Altimmune, Inc.
Price$2.94
Model IV—
P/IV—
Market implies +150.0%/yr
vs model +2.0% · above model
ALVO
Valuation N/A
Alvotech
Price$4.09
Model IV—
P/IV—
Limited data — see page
ALXO
Valuation N/A
ALX ONCOLOGY HOLDINGS INC
Price$2.06
Model IV—
P/IV—
Limited data — see page
ALZN
Valuation N/A
Alzamend Neuro, Inc.
Price$1.55
Model IV—
P/IV—
Limited data — see page
AMGN
Fairly valued
AMGEN INC
Price$415.21
Model IV$452.91
P/IV0.74
Discount 8%
Return to IV: +9.1%
Market implies +7.3%/yr
vs model +10.7% · below model
ANAB
Overvalued
ANAPTYSBIO, INC
Price$56.02
Model IV$47.56
P/IV1.17
Premium +18%
Return to IV: -15.1%
Market implies -1.0%/yr
vs model +38.8% · below model
ANIP
Deeply undervalued
ANI PHARMACEUTICALS INC
Price$74.77
Model IV$369.54
P/IV0.21
Discount 80%
Return to IV: +394.2%
Market implies -3.0%/yr
vs model +25.0% · below model
ANIX
Valuation N/A
Anixa Biosciences Inc
Price$3.42
Model IV—
P/IV—
Limited data — see page
ANL
Valuation N/A
Adlai Nortye Ltd.
Price$13.34
Model IV—
P/IV—
Limited data — see page
ANNX
Valuation N/A
Annexon, Inc.
Price$5.29
Model IV—
P/IV—
Limited data — see page
ANTX
Valuation N/A
AN2 Therapeutics, Inc.
Price$5.99
Model IV—
P/IV—
Limited data — see page
APGE
Valuation N/A
Apogee Therapeutics, Inc.
Price$134.45
Model IV—
P/IV—
Limited data — see page
APLM
Valuation N/A
Apollomics Inc.
Price$23.40
Model IV—
P/IV—
Limited data — see page
APRE
Valuation N/A
Aprea Therapeutics, Inc.
Price$0.68
Model IV—
P/IV—
Limited data — see page
APUS
Valuation N/A
Apimeds Pharmaceuticals US, Inc.
Price$4.55
Model IV—
P/IV—
Limited data — see page
APVO
Valuation N/A
Aptevo Therapeutics Inc.
Price$2.94
Model IV—
P/IV—
Market implies -13.1%/yr
vs model +15.0% · below model
ARE
Deeply undervalued
ALEXANDRIA REAL ESTATE EQUITIES, INC.
Price$48.42
Model IV$90.72
P/IV0.55
Discount 47%
Return to IV: +87.4%
ARGX
Valuation N/A
ARGENX SE
Price$856.94
Model IV—
P/IV—
Limited data — see page
ARMP
Valuation N/A
Armata Pharmaceuticals, Inc.
Price$4.56
Model IV—
P/IV—
Limited data — see page
ARQT
Deeply overvalued
Arcutis Biotherapeutics, Inc.
Price$26.19
Model IV$4.46
P/IV4.81
Premium +487%
Return to IV: -83.0%
Market implies +24.8%/yr
vs model +15.0% · above model
ARTL
Valuation N/A
ARTELO BIOSCIENCES, INC.
Price$0.79
Model IV—
P/IV—
Limited data — see page